BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » StemCyte Receives Phase II IND Clearance for HLA-Matched Cord Blood Mononuclear Stem Cells (MC001)
Stemcyte

StemCyte Receives Phase II IND Clearance for HLA-Matched Cord Blood Mononuclear Stem Cells (MC001)

January 14, 2019 By Cade Hildreth (CEO) Leave a Comment

StemCyte Receives Phase II Investigational New Drug (IND) Clearance from the U.S. Food and Drug Administration (FDA)

BALDWIN PARK, Calif., Jan. 3, 2019 — StemCyte is pleased to announce that the U.S. Food and Drug Administration (FDA), on December 14, 2018, approved its Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury.

Discover class-defining bioproduction tools.

MC001 is a regenerative cell therapy drug, which is designed to regenerate neurons in patients who suffered chronic, severe, stable spinal cord injury. MC001 has already been shown to be efficacious, safe and well tolerated in a Phase II trial conducted by Dr. Wise Young of Rutger’s University in Kunming, China. Starting in early 2019, within the United States, this Phase II study will be performed at a number of clinical centers in New Jersey.

“This is a great achievement by the StemCyte team. As a leading regenerative cell therapy company, the success of the MC001 will put StemCyte in the central position in the emerging stem cell application markets,” said Jonas Wang, StemCyte’s CEO and Chairman. “FDA’s announcement marks StemCyte having successfully reached the major milestone of the advancement of our regenerative cell therapy program. With our highly experienced expert investigators, we plan to bring this new innovative treatment option in early 2019 to this highly unmet medical need in patient populations with chronic, severe, stable spinal cord injury.”

bitbio

About StemCyte

StemCyte’s rich history started with a mission of dedication to helping the world’s physicians save more lives by providing high quality, safe, and effective stem cell transplantation and therapy to all patients in need. Located in the US, India, and Taiwan, StemCyte has supplied over 2,200 cord blood units for a variety of life-threatening diseases to over 350 leading worldwide transplant centers. StemCyte is actively involved in the development of stem cell therapies. StemCyte has also been chosen by the US Department of Health and Human Services to help establish a Public National Cord Blood Inventory. Its headquarters is located in Baldwin Park, CA. To learn more, visit www.StemCyte.com.

For more information call 626.646.2500

iPSC-derived cardiomyocte therapy

SOURCE StemCyte

Pluristyx

To learn more about the market for cord blood therapeutics, view the “Global Cord Blood Banking Industry Report.”

3.7/5 - (4 votes)

Filed Under: Cord Blood, Press Releases Tagged With: cord blood, Stemcyte

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.